Leerink Partners Downgrades CymaBay Therapeutics to Market Perform, Announces $32.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Thomas Smith downgraded CymaBay Therapeutics (CBAY) from Outperform to Market Perform and set a price target of $32.5.

February 20, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CymaBay Therapeutics was downgraded by Leerink Partners from Outperform to Market Perform with a new price target of $32.5.
The downgrade from Outperform to Market Perform by a reputable analyst could lead to mixed investor sentiment. While the establishment of a price target suggests a valuation perspective, the downgrade might temper expectations, leading to a neutral short-term impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100